Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study of the Efficacy, Safety and Tolerability of Oral CEP-701 in Patients With Severe Psoriasis

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Teva Pharmaceutical Industries ( Cephalon )
ClinicalTrials.gov Identifier:
NCT00236119
First received: October 11, 2005
Last updated: August 22, 2012
Last verified: August 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: October 2007
  Primary Completion Date: October 2007 (Final data collection date for primary outcome measure)